Alexander Pushka, MD
Child & Adolescent Psychiatry · Hollywood, FLNPI 1992793384
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 252 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Johnson & Johnson at 24.6% of the total. 2025 is the largest year on record at $2,059, 7.7 times the $268 reported in 2019. Among child & adolescent psychiatry clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 252 payments — averaging $24.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$855
- Neurocrine Biosciences, Inc.$633
- Alkermes, Inc.$627
- Teva Pharmaceuticals USA, Inc.$459
- Almatica Pharma LLC$385
- plus $2K from 13 others
Across 57 payments — averaging $10,512 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$355K
- Janssen Research & Development, LLC$136K
- Acadia Pharmaceuticals Inc$103K
- Orexo US, Inc.$5K
What the payments were for
- Food & beverage$5,95198%
- Education$1382%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 60 | $1,500 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $855 |
| Neurocrine Biosciences, Inc. | 20 | $633 |
| Alkermes, Inc. | 27 | $627 |
| Teva Pharmaceuticals USA, Inc. | 21 | $459 |
| Almatica Pharma LLC | 19 | $385 |
| Axsome Therapeutics, Inc. | 16 | $363 |
| AbbVie(2 entities) | 12 | $298 |
| Otsuka America Pharmaceutical, Inc. | 5 | $229 |
| Indivior Inc. | 7 | $175 |
| Lundbeck LLC | 8 | $169 |
| Tris Pharma Inc | 3 | $72 |
| Ironshore Pharmaceuticals Inc. | 4 | $69 |
| Supernus Pharmaceuticals, Inc. | 3 | $65 |
| Vanda Pharmaceuticals Inc. | 2 | $65 |
| Neos Therapeutics, LP | 2 | $45 |
| Collegium Pharmaceutical, Inc. | 2 | $41 |
| Bioxcel Therapeutics, Inc. | 1 | $25 |
| Luye Pharma (USA) Ltd. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$493
- INVEGA SUSTENNA$267
- SPRAVATO$125
- ABILIFY MAINTENA$125
- ARISTADA INITIO$123
How this compares
$6,090 in reported general payments places this provider in the 90th percentile of 206 child & adolescent psychiatry providers in Florida.
See all child & adolescent psychiatry providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 120 | $426,136 |
| AustedoDeutetrabenazine | 13 | $98,502 |
| Austedo XrDeutetrabenazine | 14 | $81,989 |
| RexultiBrexpiprazole | 15 | $21,469 |
| Aripiprazole | 90 | $13,842 |
| TrintellixVortioxetine Hydrobromide | 13 | $10,673 |
| Paliperidone ErPaliperidone | 57 | $8,846 |
| Quetiapine Fumarate | 235 | $4,757 |
| Duloxetine Hcl | 130 | $4,533 |
| Lurasidone Hcl | 31 | $4,388 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 117 | $3,748 |
| Bupropion XlBupropion Hcl | 122 | $3,715 |
| Clozapine | 37 | $3,692 |
| Haloperidol Decanoate | 50 | $3,341 |
| Divalproex Sodium ErDivalproex Sodium | 31 | $3,209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,500 | $426,136120 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $459 | $180,49127 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $229 | $21,46915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 206 child & adolescent psychiatry providers in Florida.
Other child & adolescent psychiatry in Hollywood
- Craig KuninsGulfport$265K
- Elias SarkisGainesville$169K
- Jeffrey AlvaroSt Petersburg$87K
- Rosa Negron MunozLakeland$39K
- Sean HoranMiami$17K
- Rachel AgustinesLargo$16K
- Carlos BorgeSarasota$15K
- Justin SpoonerPonte Vedra Beach$12K
- Bhaskar RajuOrlando$11K
- Americo PadillaMiami$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.